Lexington, MA, United States of America

Mark Wingertzahn

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Dsm Nutritional Products Inc.. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mark Wingertzahn: Innovator in Oligosaccharide Compositions

Introduction

Mark Wingertzahn is an accomplished inventor based in Lexington, MA (US). He has made significant contributions to the field of oligosaccharide compositions, particularly in their application for treating viral infections. His innovative work has the potential to impact the treatment of respiratory viral illnesses, including COVID-19.

Latest Patents

Mark Wingertzahn holds 1 patent for his invention titled "Oligosaccharide compositions and methods of use thereof for treating viral infections." This patent outlines the methods of making oligosaccharide compositions and their use as microbiome metabolic therapies. His research focuses on leveraging these compositions to combat respiratory viral illnesses effectively.

Career Highlights

Wingertzahn is associated with Dsm Nutritional Products Inc., where he continues to develop and refine his innovative ideas. His work is characterized by a commitment to advancing scientific understanding and practical applications of oligosaccharides in healthcare.

Collaborations

Throughout his career, Mark has collaborated with notable colleagues, including Jonathan Lawrence and Jeffrey Meisner. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the field.

Conclusion

Mark Wingertzahn's contributions to the field of oligosaccharide compositions demonstrate his dedication to innovation and improving health outcomes. His work continues to pave the way for new therapeutic approaches in treating viral infections.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…